Last update Aug. 30, 2018
Very High Risk
We do not have alternatives for Danazol.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Danazol belongs to this group or family:
Main tradenames from several countries containing Danazol in its composition:
|T½||4.5 - 29||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A synthetic steroid with antigonadotropic and antiestrogenic activity due to the suppression of the pituitary gland’s gonadotropic hormone and with androgenic effects (Sanofi 2017, AEMPS 2017).
Used to treat endometriosis, fibrocystic breast disease, hereditary angioedema, mastalgia, premenstrual syndrome and menorrhagia.
Administration orally twice a day.
Since the last update we have not found published data on its excretion in breastmilk or its effect on breastfed infants (Briggs 2017).
In the absence of data regarding protein binding and the volume of distribution, the known pharmacokinetic data (low molecular weight, high pKa and prolonged half-life) make it likely that it would transfer to milk in amounts which could be significant.
Due to its possible androgenic effect on the infant and inhibition of prolactin, it should be avoided during breastfeeding (Hale 2019 p193, Sanofi 2017, AEMPS 2017).